Corporate Presentation

Nasdaq CPIX

Safe Harbor Statement

This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation. For more information on our brands, including full prescribing and safety information, please see the links to the product websites which can be found at www.cumberlandpharma.com.

Nation's Health Care Capital



Company Overview

Specialty pharmaceutical company

- Portfolio of FDA approved **branded** products
- Promoted by **three** national sales divisions

Several **catalysts** for new growth opportunities

- **Sancuso®** post-acquisition integration and market expansion
- Next Generation **Caldolor®** product with **expanded labeling**
- **Vibativ®** acute care, out-patient and international initiatives

Phase II candidates in development with upcoming study milestones

Proven record of successful **product development** and product **acquisition**

Mission & Strategy

Mission: Working together to provide unique products that improve the quality of patient care

Strategy: We are building a portfolio of *specialized biopharmaceutical brands*

Product Portfolio

Product Development:

IV ACETADOTE®

CALDOLOR®

Product Acquisition:

KRISTALOSE®

VIBATIV®
(telavancin) for injection

Vaprisol®

Sancuso®
(Granisetron Transdermal System)

IV ACETADOTE®

- IV treatment for **America's leading cause of poisoning**
- **Treats liver toxicity** associated with acetaminophen overdose
- Acetadote (IV N-Acetylcysteine) **developed** and **registered** by Cumberland
- IV N-Acetycysteine now **standard of care**
- Cumberland developed **unique EDTA free formulation**

National Poison Data System, American Association of Poison Centers

CALDŌLOR®
(ibuprofen) Injection



CALDOLOR®

- **Injectable** delivery of **ibuprofen**
- **Developed** and **registered** by Cumberland
- **Antipyretic, analgesic & anti-inflammatory** properties
- Evaluated in **published studies** with ~ **2,000 patients**
- **Pediatric** labeling approved by FDA
- Use in **newborns** approved by FDA
- **Prior to surgery** administration approved by FDA

**Symphony Source Health*



KRISTALOSE®

(lactulose) For Oral Solution

KRISTALOSE®

(lactulose) For Oral Solution

- **Unique** crystalline formulation of lactulose
- Prescription strength laxative
- **Clinically proven** increase in patient satisfaction
- Featured in **award winning** marketing campaign
- Supported by key **co-promotion partners**

VIBATIV®
(telavancin) for injection



VIBATIV®
(telavancin) for injection

- IV antibiotic that treats **life-threatening infections**
- **Potent treatment** for pneumonia and serious skin infections resulting from gram positive bacteria
- Used in **hospital acute care** and **out-patient center** settings
- Unique ability to **penetrate tissues**
- Product features **favorable resistance profile**



Sancuso®
(Granisetron Transdermal System)



Sancuso®
(Granisetron Transdermal System)

- FDA-approved **transdermal system** for chemotherapy-induced nausea and vomiting
- **Patch** that slowly releases medicine into bloodstream
- Designed to prevent nausea and vomiting in adults to help tolerate certain **chemotherapy treatments**
- Medicine delivered over **five consecutive days** compared with multiple daily dosing for oral alternatives
- Supported by expanded **oncology sales division**

Sancuso® Patch

Ifetroban Overview

- Cumberland's first **new chemical entity**
- A **potent, selective** antagonist of thromboxane receptor
- Discovered and initially developed by Bristol-Myers Squibb
- **Safety well-established** in 30 clinical studies with **over 1,400 subjects**
- Collaborating with **Vanderbilt, Harvard, Scripps** and other academic centers
- Successfully manufactured **both IV** and **oral formulations**

Ifetroban Development Pipeline

Vasculan® *(Systemic sclerosis)*

Dyscorban® *(Duchenne muscular dystrophy)*

Oral Ifetroban *(Idiopathic Pulmonary Fibrosis)*

Duchenne Muscular Dystrophy (DMD)

- **A rare, fatal, neuromuscular disease** with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs
- Cumberland is investigating ifetroban for the treatment of **cardiomyopathy** that is associated with DMD
- **Preclinical data** demonstrates ifetroban could prevent cardiac fibrosis and improve cardiac function – published **Journal American Heart Association**
- The **FDA** has awarded over $1 million in **Orphan Drug Grant** funding
- Program designed to address this **unmet medical need**
- **IND cleared** and **Phase II study** is underway

Systemic Sclerosis (SSc)

- Debilitating, **chronic autoimmune disease** causing thickening of the skin and fibrosis of internal organs
- **Highest death rate** of any rheumatic condition
- Average **survival** is approximately **11 years** from diagnosis
- **Women** more commonly affected; also occurs in **children**
- No FDA approved treatment for this **unmet medical need**
- **IND cleared** and second **Phase II study** underway

Ifetroban in IPF

- Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) are a group of disorders that causes irreversible scarring (fibrosis) of lung tissue that leads to lung function decline and early mortality
- Idiopathic pulmonary fibrosis (IPF) is the most common form of PF-ILDs
- Two approved therapies for IPF slow lung function decline but are limited in practice by cost and side effects
- Orphan disease
- **IND cleared** and **Phase II study** is underway




CET®
Cumberland Emerging Technologies

CET®
Cumberland *Emerging* Technologies

- **Joint initiative** to build **long term pipeline**
- Collaborating with **Academic Research** Partners
- Building **portfolio** of innovative **biopharmaceutical candidates**
- Managing Nashville's **Life Science Center**
- Supporting product development through **grant initiatives**

Expanding Our Product Portfolio

Deploying a Multifaceted Strategy to Create Value

Commercial Portfolio Expansion Strategy

EXPAND
Existing Products

IDENTIFY
Early Stage Candidates

DEVELOP
Late-Stage Candidates

ACQUIRE
Under-Promoted, Approved Brands

PRODUCT PORTFOLIO

Acquisition Initiative

GOAL TO ADD ONE NEW PRODUCT PER YEAR

through business development initiative or internal product development

Active, ongoing initiative to identify, evaluate and acquire/license new products into the portfolio

Source opportunities through direct efforts and intermediaries

Seek commercial and late stage development assets that fit our strategy and focus

- Branded, Rx products in hospital acute care gastroenterology or oncology
- Sales of $5-25 million with attractive margins and differentiated features

Income Statement

($ IN MILLIONS)	2024, YTD
Net Revenues	**$ 27.4**
Cost of Products Sold	4.6
Gross Profit	22.8
Selling & Marketing	12.8
Research & Development	3.5
General Administrative	7.8
Amortization	3.3
Other Expense	-
Adjusted Earnings	$(0.7)

Summary Balance Sheet

($ in millions)	**September 30, 2024**
Cash and Securities	$17.5
Total Assets	**76.7**
Total Liabilities	52.3
Total Equity	24.5
Total Liabilities and Equity	**$76.7**

**tax carryforward credits of $52 million available*

Cumberland Moving Forward

Diverse product portfolio of **FDA approved brands**

Proven **development and commercialization** capabilities

Various initiatives in place to support **near-term growth**

Phase II products in development with upcoming study milestones

Valuation gap given level of sales, assets, infrastructure and pipeline

NASDAQ: CPIX